Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine

Lancet. 1979 May 5;1(8123):947-9. doi: 10.1016/s0140-6736(79)91721-5.

Abstract

Subcutaneous desferrioxamine (2--4 g over 12 h) was administered 6 nights each week to 34 patients with transfusional iron overloads who continued to receive regular blood-transfusions. All 34 patients showed a fall in serum-ferritin after 5 to 12 months. In some patients serum-ferritin fell almost to normal. Liver function improved in all the patients, serum-aspartate-transaminase levels fell in all 17 patients tested, and liver-iron fell in 5 of 6 patients tested. These studies show that body-iron stores can be substantially reduced, to normal or near normal levels, by long-term subcutaneous desferrioxamine in patients with transfusional iron overload despite the need for continued blood-transfusion. They also show that removal of iron is accompanied by improved organ function.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anemia, Aplastic / therapy
  • Anemia, Sideroblastic / therapy
  • Aspartate Aminotransferases / blood
  • Child
  • Deferoxamine / administration & dosage*
  • Female
  • Ferritins / blood
  • Follow-Up Studies
  • Hemosiderosis / drug therapy*
  • Humans
  • Infusions, Parenteral
  • Iron / metabolism*
  • Liver / metabolism*
  • Male
  • Thalassemia / therapy
  • Time Factors
  • Transfusion Reaction*

Substances

  • Ferritins
  • Iron
  • Aspartate Aminotransferases
  • Deferoxamine